RNA THERAPIES GLOBAL CLINICAL TRIAL LANDSCAPE (2024)

#DYK Did you know?



Four main **RNA therapies** in clinical trials: mRNA Vaccines, ASOs, RNAi, and Aptamers



mRNA vaccines lead, proven by their success against COVID-19

RNA therapies target any <u>gene</u>,

offering

broad

therapeutic

potential

beyond traditional drugs

targeting proteins **Pfizer and BioNTech** pioneered the mRNA COVID-19 vaccine, inspiring others

Innovative delivery methods like **lipid nanoparticles** extend half-life and reduce immunotoxicity

Global **mRNA trials** target more **infectious diseases** (AIDS, hepatitis B), **cancer, metabolic diseases** and **rare diseases** (DMD, Hemophilia) 32% OTHERS



2019 - 2023 RNA therapy trials (CAGR: 20.6%)

18%

NCOLOG

Trial Distribution:

Targeted Therapeutic areas:

50%

INFECTIOUS DISEAS

29%

ASIA-PACIFIC

24%

34%

ORTH AMERIC

13%



Fastest CAGR: Asia-Pacific (26.7%)



Trial Leaders: US, UK, Australia



Phase II (>40%)



Protein replacement therapies gaining attention among

innovators

75% of **RNA M&A** deals are acquisitions, l**ed by the US** (25% mergers)

Significant funding supports **mRNA** advancements

The content of this publication is proprietary to Novotech Health Holdings. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses. Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech. Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights. For permissions or inquiries, please contact: communications@novotech-cro.com